ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ) today announced the initial enrollments into a new landmark clinical trial designed to better identify which patients could benefit from implantable cardioverter defibrillator (ICD) therapy for the prevention of sudden cardiac arrest (SCA).
